Madrigal Pharma: What To Expect With Q4 Earnings Coming Thursday (NASDAQ:MDGL)

Last year , I initiated Madrigal Pharmaceuticals, Inc. ( MDGL ) as a Strong Buy due to the blockbuster pace of commercialization for Rezdiffra following FDA approval in March 2024. Since then, the stock has appreciated from $293 to $465, a robust gain of 58% outpacingBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior ...